The prevalence of mixed aetiology leg ulceration is likely to increase as the population becomes older, as elderly people are more likely to have arterial disease2.
Accurate assessment of venous and arterial function of the leg is therefore paramount in determining the treatment of leg ulcers3.
A targeted approach to the healing of complex wounds
A case series evaluation conducted by Professor Keith Harding, at the Welsh Wound Innovation Centre (WWIC) in Cardiff, has investigated the therapeutic effect of the geko™ device on wound healing outcomes over an 8-week period.
The case series used the geko™ device in patients with mixed aetiology leg ulceration in conjunction with appropriate or tolerable compression therapy and in arterial ulcers as a standalone therapy prior to or after surgery.
The research findings support use of the geko™ device in patients with painful venous and mixed leg ulceration in conjunction with best practice standard care. The geko™ device was effective in reducing the wound surface area and increasing the mean percentage of granulation tissue formation. 52% reported a substantial reduction in wound pain 20.
Reported as easy to use, the geko™ device facilitates self-management and empowered and engages patients and their carer’s in their care20.
Contrast speckle imaging data from a single WWIC case study (shown above) demonstrates a 225% increase in microcirculatory blood flow in the wound bed, and a 67% increase in microcirculatory blood flow surrounding the peri-wound area, after activation of the geko™ device. The increase in blood flow to the wound bed promotes conditions favourable to wound healing20.
The geko™ device is an adjunctive therapy
Consider the geko™ device for any or all of the following when:
The geko™ device can contribute to a reduction in the costs of unnecessary call out for community nursing teams or unscheduled visits to wound clinics. Patients are enabled to self-manage the geko™ device to take control over their symptoms whilst resuming their normal daily activities.